Info: Read More
  • 中药标准品生产商,产品定制服务
  • 黄卡瓦胡椒素A; 2'- 羟基-4,4',6'-三甲氧基查耳酮

    Flavokawain A

    黄卡瓦胡椒素A; 2'- 羟基-4,4',6'-三甲氧基查耳酮
    产品编号 CFN98446
    CAS编号 3420-72-2
    分子式 = 分子量 C18H18O5 = 314.3
    产品纯度 >=98%
    物理属性 Yellow powder
    化合物类型 Chalcones
    植物来源 The roots of Piper methysticum
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    黄卡瓦胡椒素A; 2'- 羟基-4,4',6'-三甲氧基查耳酮 CFN98446 3420-72-2 1mg QQ客服:215959384
    黄卡瓦胡椒素A; 2'- 羟基-4,4',6'-三甲氧基查耳酮 CFN98446 3420-72-2 5mg QQ客服:215959384
    黄卡瓦胡椒素A; 2'- 羟基-4,4',6'-三甲氧基查耳酮 CFN98446 3420-72-2 10mg QQ客服:215959384
    黄卡瓦胡椒素A; 2'- 羟基-4,4',6'-三甲氧基查耳酮 CFN98446 3420-72-2 20mg QQ客服:215959384
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Vin?a Institute of Nuclear Sciences (Serbia)
  • Medical University of South Carolina (USA)
  • Texas A&M University (USA)
  • Donald Danforth Plant Science Center (USA)
  • University of Hull (United Kingdom)
  • National Research Council of Canada (Canada)
  • University of Indonesia (Indonesia)
  • Warszawski Uniwersytet Medyczny (Poland)
  • Florida A&M University (USA)
  • University Medical Center Mainz (Germany)
  • Korea Institute of Oriental Medicine (Korea)
  • Siksha O Anusandhan University (India)
  • Monash University Malaysia (Malaysia)
  • University of Vienna (Austria)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Drug Chem Toxicol.2020, 1-14.
  • Asian Pac J Tropical Bio.2020, 10(6):239-247
  • Int J Food Sci Nutr.2019, 70(7):825-833
  • Rev. Chim.2020, 71(3),558-564
  • J Biomol Struct Dyn.2022, 5;1-17.
  • Evid Based Complement Alternat Med.2021, 8707280.
  • J Cell Mol Med.2023, 27(11):1592-1602.
  • Int J Mol Sci.2015, 16(8):18396-411
  • Antioxidants (Basel).2022, 11(8):1471.
  • FEBS Lett.2015, 589(1):182-7
  • J Cell Mol Med.2020, 24(21):12308-12317.
  • Curr Top Med Chem.2020, 20(21):1898-1909.
  • Metabolites.2020, 11(1):E11.
  • SRM Institute of Sci&Tech2022, 34(1): 32-37
  • J Cachexia Sarcopenia Muscle.2022, 13(6):3149-3162.
  • Sci Rep.2017, 7:467-479
  • Molecules.2022, 27(22):7887.
  • J Med Food.2022, 25(3):272-280.
  • Biomed Pharmacother.2019, 116:108987
  • Enzyme Microb Technol.2019, 122:64-73
  • Front Pharmacol.2021, 12:690113.
  • Molecules.2023, 28(19):6775.
  • Phytomedicine.2019, 59:152785
  • ...
  • 生物活性
    Description: Flavokawain A is an apoptotic inducer and immune- modulator ,it also shows anti-inflammatory, and anti-tumor activities.Flavokawain A can significantly reduce the expression of CDK1-inhibitory kinases, Myt1 and Wee1, and cause cyclin B1 protein accumulation leading to CDK1 activation in T24 cells.Flavokawain A may suppress LPS-induced expression of pro-inflammatory mediators via blockage of NF-κB-AP-1-JNK/p38 MAPK signaling pathways in the murine macrophages.
    Targets: NF-kB | AP-1 | JNK | p38MAPK | TNF-α | CDK | NOS | COX | NO | PGE | IL Receptor | p53 | p21
    In vitro:
    Food Chem Toxicol. 2013 Aug;58:479-86.
    Suppression of iNOS and COX-2 expression by flavokawain A via blockade of NF-κB and AP-1 activation in RAW 264.7 macrophages.[Pubmed: 23727179 ]
    Flavokawain A, a major constituent of chalcones derived from kava extracts, exerts various biological activities such as anti-tumor activities.
    METHODS AND RESULTS:
    In this study, we examined the suppressive effect of flavokawain A on LPS-induced expression of pro-inflammatory mediators and the molecular mechanisms responsible for these activities in the murine macrophages. Flavokawain A significantly suppressed expression of iNOS and COX-2, as well as the subsequent production of NO and PGE2 in the LPS-stimulated RAW 264.7 cells. Flavokawain A significantly inhibited LPS-induced activation of NF-κB and AP-1 signaling pathways. In addition, flavokawain A inhibited activation of JNK and p38 MAPK which was responsible for expression of iNOS and COX-2 in the LPS-stimulated RAW 264.7 cells. Furthermore, flavokawain A suppressed LPS-induced expression of pro-inflammatory cytokines, such as TNF-α, IL-1β and IL-6.
    CONCLUSIONS:
    These results suggest that flavokawain A may exert anti-inflammatory responses by suppressing LPS-induced expression of pro-inflammatory mediators via blockage of NF-κB-AP-1-JNK/p38 MAPK signaling pathways in the murine macrophages.
    PLoS One. 2014 Oct 6;9(10):e105244.
    Flavokawain A induces apoptosis in MCF-7 and MDA-MB231 and inhibits the metastatic process in vitro.[Pubmed: 25286005]
    The kava-kava plant (Piper methsyticum) is traditionally known as the pacific elixir by the pacific islanders for its role in a wide range of biological activities. The extract of the roots of this plant contains a variety of interesting molecules including Flavokawain A and this molecule is known to have anti-cancer properties. Breast cancer is still one of the leading diagnosed cancers in women today. The metastatic process is also very pertinent in the progression of tumorigenesis.
    METHODS AND RESULTS:
    MCF-7 and MDA-MB231 cells were treated with several concentrations of FKA. The apoptotic analysis was done through the MTT assay, BrdU assay, Annexin V analysis, cell cycle analysis, JC-1 mitochondrial dye, AO/PI dual staining, caspase 8/9 fluorometric assay, quantitative real time PCR and western blot. For the metastatic assays, the in vitro scratch assay, trans-well migration/invasion assay, HUVEC tube formation assay, ex vivo rat aortic ring assay, quantitative real time PCR and western blot were employed. We have investigated the effects of FKA on the apoptotic and metastatic process in two breast cancer cell lines. FKA induces apoptosis in both MCF-7 and MDA-MB231 in a dose dependent manner through the intrinsic mitochondrial pathway. Additionally, FKA selectively induces a G2/M arrest in the cell cycle machinery of MDA-MB231 and G1 arrest in MCF-7. This suggests that FKA's anti-cancer activity is dependent on the p53 status. Moreover, FKA also halted the migration and invasion process in MDA-MB231. The similar effects can be seen in the inhibition of the angiogenesis process as well.
    CONCLUSIONS:
    FKA managed to induce apoptosis and inhibit the metastatic process in two breast cancer cell lines, in vitro. Overall, FKA may serve as a promising candidate in the search of a new anti-cancer drug especially in halting the metastatic process but further in vivo evidence is needed.
    Cancer Res. 2005 Apr 15;65(8):3479-86.
    Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice.[Pubmed: 15833884]
    Consumption of the traditional kava preparation was reported to correlate with low and uncustomary gender ratios (more cancer in women than men) of cancer incidences in three kava-drinking countries: Fiji, Vanuatu, and Western Samoa. We have identified flavokawain A, B, and C but not the major kavalactone, kawain, in kava extracts as causing strong antiproliferative and apoptotic effect in human bladder cancer cells.
    METHODS AND RESULTS:
    Flavokawain A results in a significant loss of mitochondrial membrane potential and release of cytochrome c into the cytosol in an invasive bladder cancer cell line T24. These effects of flavokawain A are accompanied by a time-dependent decrease in Bcl-x(L), a decrease in the association of Bcl-x(L) to Bax, and an increase in the active form of Bax protein. Using the primary mouse embryo fibroblasts Bax knockout and wild-type cells as well as a Bax inhibitor peptide derived from the Bax-binding domain of Ku70, we showed that Bax protein was, at least in part, required for the apoptotic effect of flavokawain A. In addition, flavokawain A down-regulates the expression of X-linked inhibitor of apoptosis and survivin.
    CONCLUSIONS:
    Because both X-linked inhibitor of apoptosis and survivin are main factors for apoptosis resistance and are overexpressed in bladder tumors, our data suggest that flavokawain A may have a dual efficacy in induction of apoptosis preferentially in bladder tumors. Finally, the anticarcinogenic effect of flavokawain A was evident in its inhibitory growth of bladder tumor cells in a nude mice model (57% of inhibition) and in soft agar.
    In vivo:
    Cancer Prev Res (Phila). 2013 Dec;6(12):1365-75.
    Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.[Pubmed: 24121102]
    Flavokawain A (FKA) is the predominant chalcone identified from the kava plant. We have previously shown that FKA preferentially inhibits the growth of p53 defective bladder cancer cell lines.
    METHODS AND RESULTS:
    Here, we examined whether FKA could inhibit bladder cancer development and progression in vivo in the UPII-SV40T transgenic model that resembles human urothelial cell carcinoma (UCC) with defects in the p53 and the retinoblastoma (Rb) protein pathways. Genotyped UPII-SV40T mice were fed orally with vehicle control (AIN-93M) or FKA (6 g/kg food; 0.6%) for 318 days starting at 28 days of age. More than 64% of the male mice fed with FKA-containing food survived beyond 318 days of age, whereas only about 38% of the male mice fed with vehicle control food survived to that age (P = 0.0383). The mean bladder weights of surviving male transgenic mice with the control diet versus the FKA diet were 234.6 ± 72.5 versus 96.1 ± 69.4 mg (P = 0.0002). FKA was excreted primarily through the urinary tract and concentrated in the urine up to 8.4 μmol/L, averaging about 38 times (males) and 15 times (females) more concentrated than in the plasma (P = 0.0001). FKA treatment inhibited the occurrence of high-grade papillary UCC, a precursor to invasive urothelial cancer, by 42.1%. A decreased expression of Ki67, survivin, and X-linked inhibitor of apoptotic proteins (XIAP) and increased expression of p27 and DR5, and the number of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive apoptotic cells were observed in the urothelial tissue of FKA-fed mice.
    CONCLUSIONS:
    These results suggest a potential of FKA in preventing the recurrence and progression of non-muscle-invasive UCC.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.1817 mL 15.9084 mL 31.8167 mL 63.6335 mL 79.5418 mL
    5 mM 0.6363 mL 3.1817 mL 6.3633 mL 12.7267 mL 15.9084 mL
    10 mM 0.3182 mL 1.5908 mL 3.1817 mL 6.3633 mL 7.9542 mL
    50 mM 0.0636 mL 0.3182 mL 0.6363 mL 1.2727 mL 1.5908 mL
    100 mM 0.0318 mL 0.1591 mL 0.3182 mL 0.6363 mL 0.7954 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    2',4',6',4-四甲氧基查耳酮; 2',4',6',4-Tetramethoxychalcone CFN91683 94103-36-3 C19H20O5 = 328.4 5mg QQ客服:215959384
    2',4'-二羟基-2,3',6'- 三甲氧基查尔酮; 2',4'-Dihydroxy-2,3',6'-trimethoxychalcone CFN99015 100079-39-8 C18H18O6 = 330.3 5mg QQ客服:3257982914
    3'-Methylflavokawin; 3'-Methylflavokawin CFN96084 1044743-35-2 C18H18O5 = 314.3 5mg QQ客服:1413575084
    3'-甲基-2',4'-二羟基-4,6'-二甲氧基查耳酮 ; 3'-Methyl-4-O-methylhelichrysetin CFN96164 109471-13-8 C18H18O5 = 314.3 5mg QQ客服:215959384
    4,4'-二甲氧基查耳酮; 4,4'-Dimethoxychalcone CFN70472 2373-89-9 C17H16O3 = 268.3 5mg QQ客服:215959384
    异甘草素; 4,2',4'-三羟基查耳酮; Isoliquiritigenin CFN97542 961-29-5 C15H12O4 = 256.3 20mg QQ客服:1413575084
    2''-O-甲基异甘草苷元; 4,4'-二羟基-2'-甲氧基查耳酮; 2'-O-Methylisoliquiritigenin CFN98832 51828-10-5 C16H14O4 = 270.3 5mg QQ客服:1413575084
    3-去氧苏木查耳酮; 3-Deoxysappanchalcone CFN92833 112408-67-0 C16H14O4 = 270.3 5mg QQ客服:215959384
    4,2'-Dihydroxy-4'-methoxychalcone ; 4,2'-Dihydroxy-4'-methoxychalcone CFN89427 63529-06-6 C16H14O4 = 270.28 5mg QQ客服:2056216494
    根皮素; Phloretin CFN97040 60-82-2 C15H14O5 = 274.3 20mg QQ客服:215959384

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产